Article
PXR polymorphisms have impact on the clinical efficacy of clopidogrel in patients undergoing percutaneous coronary intervention.
Gene - 5 May 2018
Wu Yan, Yu Hua, Tang Hai-Qin, Su Yong, Shi Tian-Lu, Liu Sheng, Xia Quan, Xu Du-Juan
Abstract excerpt
BACKGROUNDS: Clopidogrel is widely used in Coronary Heart Disease (CHD) patients undergoing percutaneous coronary intervention (PCI) to prevent thrombotic events. However, clopidogrel response variability (CRV) may affect the patients' clinical outcomes. The current data have shown that genetic factors play an important role in CRV. The aim of this research is to investigate the association of pregnane X receptor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
